• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.头孢哌酮-舒巴坦针对多重耐药菌的合适复方制剂。
Infect Drug Resist. 2018 Sep 11;11:1441-1445. doi: 10.2147/IDR.S175257. eCollection 2018.
2
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.接种物量对头孢哌酮-舒巴坦对多药耐药菌活性的影响。
J Microbiol Immunol Infect. 2018 Apr;51(2):207-213. doi: 10.1016/j.jmii.2017.08.026. Epub 2017 Oct 6.
3
In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products.多种头孢哌酮/舒巴坦产品的体外抗菌活性
Antibiotics (Basel). 2020 Feb 12;9(2):77. doi: 10.3390/antibiotics9020077.
4
In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant and .头孢哌酮及头孢哌酮-舒巴坦对碳青霉烯类耐药菌的体外活性及……（原文此处不完整）
Infect Drug Resist. 2018 Dec 20;12:25-29. doi: 10.2147/IDR.S181201. eCollection 2019.
5
Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?头孢哌酮/舒巴坦：针对多重耐药革兰氏阴性菌的新型复合制剂？
Infect Genet Evol. 2021 Mar;88:104707. doi: 10.1016/j.meegid.2021.104707. Epub 2021 Jan 5.
6
Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against .舒巴坦增强β-内酰胺类抗生素的体外活性对抗…… （原文此处不完整）
Infect Drug Resist. 2021 Sep 28;14:3971-3977. doi: 10.2147/IDR.S332160. eCollection 2021.
7
Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.头孢哌酮-他唑巴坦与头孢哌酮-舒巴坦联合用药对呼吸道和泌尿系统感染中产生超广谱β-内酰胺酶（ESBL）病原体的体外活性比较
J Assoc Physicians India. 2012 Nov;60:22-4.
8
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].舒巴坦与亚胺培南、美罗培南和头孢哌酮联合对耐碳青霉烯类鲍曼不动杆菌分离株的体外协同活性
Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104.
9
Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.产 ESBL 肠杆菌科细菌血流感染的头孢哌酮/舒巴坦与碳青霉烯类经验性治疗的比较。
J Antimicrob Chemother. 2018 Nov 1;73(11):3176-3180. doi: 10.1093/jac/dky323.
10
The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.头孢哌酮-舒巴坦联合制剂。体外特性，包括β-内酰胺酶稳定性、抗菌活性以及纸片扩散法检测的解释标准。
Am J Clin Pathol. 1985 Oct;84(4):496-504. doi: 10.1093/ajcp/84.4.496.

引用本文的文献

1
Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.头孢哌酮-舒巴坦作为重症监护病房耐碳青霉烯鲍曼不动杆菌血流感染联合治疗方案组成部分的疗效：一项多中心回顾性倾向评分匹配研究
BMC Infect Dis. 2025 Jul 1;25(1):872. doi: 10.1186/s12879-025-11205-w.
2
In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing Uropathogenic .头孢克洛/β-内酰胺酶抑制剂（克拉维酸和舒巴坦）联合用药对产超广谱β-内酰胺酶的尿路致病性病原菌的体外活性
Antibiotics (Basel). 2025 Jun 13;14(6):603. doi: 10.3390/antibiotics14060603.
3
Aeromonas veronii-associated bacteremia in the course of treatment of acute myeloid leukemia: a case report and review of the literature.维氏气单胞菌所致菌血症伴急性髓系白血病治疗过程：一例报告及文献复习
Discov Oncol. 2024 Sep 27;15(1):493. doi: 10.1007/s12672-024-01362-w.
4
Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment.多中心研究：头孢哌酮/舒巴坦治疗肺炎克雷伯菌血症患者的临床结局和不良预后因素。
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1777-1785. doi: 10.1007/s10096-024-04892-x. Epub 2024 Jul 12.
5
Evaluation of the in vitro activity of ampicillin-sulbactam and cefoperazone-sulbactam against A. Baumannii by the broth disk elution test.采用肉汤稀释法测定氨苄西林-舒巴坦和头孢哌酮-舒巴坦对鲍曼不动杆菌的体外活性。
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1711-1719. doi: 10.1007/s10096-024-04889-6. Epub 2024 Jul 6.
6
Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia.新型铁载体头孢菌素及头孢菌素与β-内酰胺酶抑制剂的联合用药作为呼吸机相关性肺炎治疗的进展
Antibiotics (Basel). 2024 May 14;13(5):445. doi: 10.3390/antibiotics13050445.
7
Active metabolites combination therapies: towards the next paradigm for more efficient and more scientific Chinese medicine.活性代谢物联合疗法：迈向更高效、更科学的中药新范式。
Front Pharmacol. 2024 Apr 18;15:1392196. doi: 10.3389/fphar.2024.1392196. eCollection 2024.
8
Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli.头孢吡肟-他唑巴坦合剂对产超广谱β-内酰胺酶和/或AmpCβ-内酰胺酶革兰阴性杆菌的抗菌活性。
BMC Infect Dis. 2024 Apr 23;24(1):434. doi: 10.1186/s12879-024-09296-y.
9
Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis.不同比例头孢哌酮/舒巴坦治疗肾盂肾炎患者的比较。
Pak J Med Sci. 2023 Jan-Feb;39(1):55-59. doi: 10.12669/pjms.39.1.6850.
10
Deciphering the Role of -Lactamase Inhibitors, Membrane Permeabilizers and Efflux Pump Inhibitors as Emerging Targets in Antibiotic Resistance.解析β-内酰胺酶抑制剂、膜通透剂和外排泵抑制剂作为抗生素耐药性新兴靶点的作用
Indian J Microbiol. 2022 Dec;62(4):524-530. doi: 10.1007/s12088-022-01045-6. Epub 2022 Oct 28.

本文引用的文献

1
An update on β-lactamase inhibitor discovery and development.β-内酰胺酶抑制剂的发现和发展研究进展
Drug Resist Updat. 2018 Jan;36:13-29. doi: 10.1016/j.drup.2017.11.002. Epub 2017 Nov 7.
2
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.美罗培南和瓦博巴坦：加强对抗碳青霉烯类耐药肠杆菌科细菌的战斗。
Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28.
3
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.亚胺培南-西司他丁钠和美罗培南-法硼巴坦：两种新型碳青霉烯-β-内酰胺酶抑制剂复方制剂。
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
4
β-Lactamase inhibitors: what you really need to know.β-内酰胺酶抑制剂：您真正需要了解的内容。
Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27.
5
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.接种物量对头孢哌酮-舒巴坦对多药耐药菌活性的影响。
J Microbiol Immunol Infect. 2018 Apr;51(2):207-213. doi: 10.1016/j.jmii.2017.08.026. Epub 2017 Oct 6.
6
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.新型β-内酰胺酶抑制剂：挖掘其治疗潜力
Drugs. 2017 Apr;77(6):615-628. doi: 10.1007/s40265-017-0725-1.
7
The role of doxycycline in the therapy of multidrug-resistant E. coli - an in vitro study.多西环素在治疗多重耐药大肠杆菌中的作用。一项体外研究。
Sci Rep. 2016 Aug 18;6:31964. doi: 10.1038/srep31964.
8
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
9
Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii.舒巴坦在多重耐药鲍曼不动杆菌中的协同作用。
Braz J Microbiol. 2015 Oct-Dec;46(4):1119-24. doi: 10.1590/S1517-838246420140101.
10
Three decades of beta-lactamase inhibitors.三十年的β-内酰胺酶抑制剂。
Clin Microbiol Rev. 2010 Jan;23(1):160-201. doi: 10.1128/CMR.00037-09.

头孢哌酮-舒巴坦针对多重耐药菌的合适复方制剂。

Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.

作者信息

Lai Chih-Cheng, Chen Chi-Chung, Lu Ying-Chen, Lin Tsuey-Pin, Chuang Yin-Ching, Tang Hung-Jen

机构信息

Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying.

Department of Medical Research, Chi Mei Medical Center, Tainan.

出版信息

Infect Drug Resist. 2018 Sep 11;11:1441-1445. doi: 10.2147/IDR.S175257. eCollection 2018.

DOI:10.2147/IDR.S175257
PMID:30237728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6138961/
Abstract

OBJECTIVES

This study aims to assess the in vitro activity of different cefoperazone-sulbactam ratios against different multidrug-resistant organisms (MDROs).

MATERIALS AND METHODS

Minimum inhibitory concentrations (MICs) and susceptibility rates of cefoperazone, sulbactam and cefoperazone-sulbactam at fixed ratios of 2:1, 1:1 and 1:2 against 344 MDRO clinical isolates, including extended-spectrum β-lactamase (ESBL)-producing (n=58), ESBL-producing (n=58), carbapenem-resistant (n=57), carbapenem-resistant (n=49) and carbapenem-resistant (n=122), were measured.

RESULTS

Combined treatment with sulbactam and cefoperazone resulted in decreased MIC values across all MDROs, as well as decreases in most MIC values, except for carbapenem-resistant and carbapenem-resistant (MIC values remained >64 mg/L). Susceptibility rates of treatment with cefoperazone alone against all MDROs were much lower than that of cefoperazone-sulbactam combination (all <0.05), except in carbapenem-resistant . Additionally, the susceptibility rate gradually increased as the ratio of cefoperazone-sulbactam was adjusted from 2:1 to 1:1 and to 1:2 for carbapenem-resistant Enterobacteriaceae, ESBL-producing and carbapenem-resistant . There were no significant ratio-dependent changes in susceptibility rates with cefoperazone-sulbactam in carbapenem-resistant .

CONCLUSION

Adding sulbactam enhances cefoperazone activity against most MDROs excluding carbapenem-resistant , and the activity of cefoperazone-sulbactam against these MDROs is greatest at a ratio of 1:2, followed by ratios of 1:1 and 2:1.

摘要

目的

本研究旨在评估不同头孢哌酮 - 舒巴坦比例对不同多重耐药菌（MDROs）的体外活性。

材料与方法

测定头孢哌酮、舒巴坦以及固定比例为2:1、1:1和1:2的头孢哌酮 - 舒巴坦对344株MDRO临床分离株的最低抑菌浓度（MICs）和药敏率，这些分离株包括产超广谱β - 内酰胺酶（ESBL）的（n = 58）、产ESBL的（n = 58）、耐碳青霉烯类的（n = 57）、耐碳青霉烯类的（n = 49）和耐碳青霉烯类的（n = 122）。

结果

舒巴坦与头孢哌酮联合治疗使所有MDROs的MIC值降低，除耐碳青霉烯类和耐碳青霉烯类外（MIC值仍>64 mg/L），大多数MIC值也降低。单独使用头孢哌酮治疗所有MDROs的药敏率远低于头孢哌酮 - 舒巴坦联合治疗（均<0.05），耐碳青霉烯类除外。此外，对于耐碳青霉烯类肠杆菌科细菌、产ESBL的和耐碳青霉烯类，随着头孢哌酮 - 舒巴坦比例从2:1调整为1:1再到1:2，药敏率逐渐升高。头孢哌酮 - 舒巴坦对耐碳青霉烯类的药敏率没有显著的比例依赖性变化。

结论

添加舒巴坦可增强头孢哌酮对除耐碳青霉烯类外的大多数MDROs的活性，头孢哌酮 - 舒巴坦对这些MDROs的活性在比例为1:2时最大，其次是1:1和2:1的比例。